J&J: ends trial on treatment for depression
(CercleFinance.com) - Johnson & Johnson announced last night that it had decided to terminate a phase 3 study of aticaprant in major depressive disorder, an announcement which had no impact on its share price.
In a press release published on its website, J&J justifies its decision on the basis of efficacy, which in its view was “insufficient” to justify the continuation of these trials in the target population.
However, the US pharmaceutical group says that these data showed that aticaprant had a good safety profile and was well tolerated by patients, leading it to consider developing the drug in other therapeutic areas.
Johnson & Johnson also confirms its ambition to become the world leader in the neuroscience sector, i.e. neuropsychiatric and neurodegenerative disorders, as illustrated by its recent acquisition of Intra-Cellular Therapies.
On the New York Stock Exchange, J&J shares were up 0.6% on Friday morning despite this disappointment.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
In a press release published on its website, J&J justifies its decision on the basis of efficacy, which in its view was “insufficient” to justify the continuation of these trials in the target population.
However, the US pharmaceutical group says that these data showed that aticaprant had a good safety profile and was well tolerated by patients, leading it to consider developing the drug in other therapeutic areas.
Johnson & Johnson also confirms its ambition to become the world leader in the neuroscience sector, i.e. neuropsychiatric and neurodegenerative disorders, as illustrated by its recent acquisition of Intra-Cellular Therapies.
On the New York Stock Exchange, J&J shares were up 0.6% on Friday morning despite this disappointment.
Copyright (c) 2025 CercleFinance.com. All rights reserved.